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Abstract
Breast	cancer	and	melanoma	are	among	the	most	frequent	cancer	types	leading	to	
brain	metastases.	Despite	the	unquestionable	clinical	significance,	important	aspects	
of	the	development	of	secondary	tumours	of	the	central	nervous	system	are	largely	
uncharacterized,	including	extravasation	of	metastatic	cells	through	the	blood-	brain	
barrier.	By	using	transmission	electron	microscopy,	here	we	followed	interactions	of	
cancer	cells	and	brain	endothelial	cells	during	the	adhesion,	intercalation/incorpora-
tion	and	transendothelial	migration	steps.	We	observed	that	brain	endothelial	cells	
were	actively	involved	in	the	initial	phases	of	the	extravasation	by	extending	filopodia-	
like	membrane	protrusions	towards	the	tumour	cells.	Melanoma	cells	tended	to	inter-
calate	 between	 endothelial	 cells	 and	 to	 transmigrate	 by	 utilizing	 the	 paracellular	
route.	On	the	other	hand,	breast	cancer	cells	were	frequently	incorporated	into	the	
endothelium	and	were	able	to	migrate	through	the	transcellular	way	from	the	apical	
to	the	basolateral	side	of	brain	endothelial	cells.	When	co-	culturing	melanoma	cells	
with	cerebral	 endothelial	 cells,	we	observed	N-	cadherin	enrichment	at	melanoma-	
melanoma	and	melanoma-	endothelial	cell	borders.	However,	for	breast	cancer	cells	
N-	cadherin	proved	to	be	dispensable	for	the	transendothelial	migration	both	in	vitro	
and	 in	vivo.	Our	 results	 indicate	 that	breast	 cancer	cells	 are	more	effective	 in	 the	
transcellular	type	of	migration	than	melanoma	cells.
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1  | INTRODUCTION
Brain	metastases	are	devastating	complications	of	lung	or	breast	carci-
noma,	melanoma	and	other	cancer	types,	characterized	by	challenging	
treatment	options.1,2	Melanoma	is	the	third	most	common	source	of	
brain	metastases,3	but	has	the	highest	risk	to	spread	into	the	central	
nervous	system	(CNS).4	Brain	metastatic	 lesions	can	be	found	in	ap-
proximately	three	of	four	patients	dying	of	melanoma.5	Breast	cancer	is	
the	second	most	frequent	cause	of	CNS	metastases.3	Among	different	
subtypes,	 triple	negative	 (ie	negative	for	estrogen	and	progesterone	
hormone	receptors	and	also	for	Her2/human	epidermal	growth	factor	
receptor	2)	and	Her2-	enriched	(ie	negative	for	hormone	receptors	and	
positive	for	Her2)	mammary	tumours	are	the	most	prone	to	give	sec-
ondary	brain	tumours.6	Incidence	proportion	of	brain	metastases	was	
found	to	be	11.37%	and	11.45%	 in	patients	having	metastatic	 triple	
negative	or	metastatic	Her2-	enriched	breast	tumours,	respectively.7
In	 brain	 metastatic	 melanoma,	 novel	 systemic	 targeted	 thera-
pies	and	immunotherapies	significantly	increased	the	median	overall	
survival	of	the	patients;	however,	it	is	still	below	2	years.8,9	Among	
patients	with	breast	cancer	brain	metastasis,	the	median	overall	sur-
vival	time	was	reported	to	be	6	months	for	the	triple	negative	sub-
type	and	10	months	for	the	Her2-	enriched	subtype.7
Considering	 this	poor	prognosis,	new	treatment	and	prevention	
strategies	are	urgently	needed,10	which	 imply	understanding	of	 the	
mechanisms	 involved.	 Development	 of	metastases	 of	 the	 CNS	 de-
pends	on	the	unique	interaction	between	tumour	cells	and	cells	of	the	
neurovascular	unit	 (NVU).11	 It	has	been	suggested	that	both	blood-	
brain	 barrier	 (BBB)-	forming	 tightly	 interconnected	 endothelial	 cells	
and	glial	cells	have	a	Janus-	faced	attitude	towards	cancer	cells,	that	is	
killing	the	vast	majority	of	brain	invading	metastatic	cells,	but	protect-
ing	those	which	are	able	to	overcome	the	detrimental	mechanisms.12
Here	we	addressed	the	first	unique	step	of	brain	metastasis	for-
mation,	that	 is	diapedesis	of	tumour	cells	through	the	cerebral	en-
dothelium.	Interconnected	by	continuous	tight	junctions	(TJs),	brain	
endothelial	cells	form	the	tightest	endothelial	barrier	 in	the	organ-
ism13;	therefore,	extravasation	of	metastatic	cells	through	this	highly	
restrictive	vasculature	is	a	key	step	in	the	development	of	secondary	
brain	tumours.	After	adhesion	to	the	luminal	surface	of	endothelial	
cells,	cancer	cells	may	incorporate	into	the	endothelial	monolayer,14 
followed	by	the	transmigration	step.
Transendothelial	 migration	 of	 tumour	 cells	 might	 involve	 dis-
ruption	of	 the	TJs	and	consequently	the	paracellular	movement	of	
the	 tumour	 cells.	We	 have	 previously	 demonstrated	 the	 ability	 of	
melanoma	cells	to	breach	the	junctional	complex	of	cerebral	endo-
thelial	cells	 (CECs)	 through	direct	contact	and	secretion	of	soluble	
factors.15,16	Not	 only	 TJs,	 but	 adherens	 junctions	 (AJs)	might	 also	
be	involved	in	this	process,	especially	the	transmembrane	cadherin	
proteins.	In	non-	brain	endothelial	cells,	N-	cadherin	was	observed	to	
participate	in	the	formation	of	heterocellular	contacts	between	tu-
mour	cells	and	endothelial	cells	during	transendothelial	migration	of	
melanoma	cells.17	N-	cadherin	 is	up-	regulated	in	response	to	trans-
forming	growth	factor-	β	(TGF-	β)	released	by	metastatic	cells,	leading	
to	an	 increase	 in	 the	ability	of	melanoma	cells	 to	attach	 to	and	 to	
migrate	through	CECs.18
Besides	 the	 paracellular	 route,	 brain-	invading	 cells	 might	 also	
take	the	transcellular	way,	through	individual	endothelial	cells.	Our	
previous	 results	 raised	 the	 possibility	 of	 transcellular	migration	of	
breast	cancer	cells16;	however,	no	direct	evidence	of	the	movement	
of	cancer	cells	through	the	cell	body	of	CECs	has	existed	so	far.
By	using	high	resolution	transmission	electron	microscopy	(TEM),	
here	we	aimed	to	investigate	the	transmigration	routes	of	melanoma	
and	 triple	 negative	 breast	 cancer	 cells	 through	 brain	 endothelial	
cells.	In	addition,	involvement	of	N-	cadherin	in	these	processes	was	
also	assessed.
2  | MATERIAL AND METHODS
2.1 | Cell culture and in vitro models
A2058	human	melanoma	cells	(obtained	from	the	European	Collection	
of	Authenticated	Cell	Cultures)	were	maintained	in	Minimum	Essential	
Medium	(MEM)	Eagle	with	Earle's	salts	and	non-	essential	amino	acids	
(Sigma	Aldrich)	supplemented	with	5%	foetal	bovine	serum	(FBS,	Sigma	
Aldrich,	St	Louis,	MI,	USA)	and	Glutamax	(Thermo	Fischer	Scientific,	
Waltham,	MA,	USA).	 B16/F10	murine	melanoma	 cells	were	 kept	 in	
Roswell	Park	Memorial	 Institute	 (RPMI)	1640	medium	(Pan	Biotech,	
Aidenbach,	Germany)	supplemented	with	5%	FBS	(PAA	Laboratories)	
and	 Glutamax.	 MDA-	MB-	231	 human	 triple	 negative	 breast	 can-
cer	cells	were	kept	 in	Dulbecco's	Modified	Eagle's	medium	(DMEM)	
medium	(Sigma	Aldrich)	supplemented	with	5%	FBS	 (Sigma	Aldrich).	
Enhanced	green	fluorescent	protein	(EGFP)-	expressing	MDA-	MB-	231	
cells	were	obtained	by	 transfection	of	 the	cells	with	 the	pEGFP-	C1	
plasmid	using	TurboFect	reagent	(Thermo	Fischer	Scientific)	and	se-
lection	with	G418	(Thermo	Fischer	Scientific).	4T1	mouse	triple	nega-
tive	breast	cancer	cells	were	cultured	in	RPMI	1640	containing	5%	FBS	
(PAA	Laboratories)	and	Glutamax.	TdTomato-	4T1	cells	were	obtained	
by	transfection	of	the	cells	with	the	pcDNA3.1(+)/Luc2	=	tdT	plasmid	
using	Lipofectamine	2000	(Thermo	Fischer	Scientific)	and	selected	by	
single	cell	cloning	after	sorting	with	a	BD	FACSAria	Fusion	flow	cy-
tometer.	For	 further	 selection,	 tdTomato-	4T1	cells	were	cultured	 in	
G418-	containing	medium.	EmGFP	(emerald	GFP)-	expressing	4T1	cells	
were	 prepared	 by	 retroviral	 transfection,	 as	 described	 elsewhere19 
and	selected	on	blasticidin	S	(Sigma	Aldrich).	The	hCMEC/D3	human	
cerebral	 endothelial	 microvascular	 cells	 (abbreviated	 D3;	 obtained	
from	 Pierre-	Olivier	 Couraud,	 Institut	 Cochin,	 Paris,	 France)	 were	
grown	on	 rat	 tail	 collagen-	coated	dishes	 in	Endothelial	Cell	Growth	
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Medium-	2	(EGM-	2)	Endothelial	Bullet	Kit	including	basal	medium	and	
supplements	(Lonza)	and	2.5%	FBS	(Sigma	Aldrich).	All	cell	lines	were	
routinely	tested	for	mycoplasma	infection.
Primary	rat	brain	endothelial	cells	 (RBECs)	were	 isolated	from	2-	to	
3-	week-	old	rats.20	After	the	removal	of	meninges,	cerebral	cortices	were	
cut	into	small	pieces	and	digested	with	1	mg/mL	collagenase	type	2	(Sigma	
Aldrich)	for	75	minutes	at	37°C.	After	separation	of	myelin	by	centrifu-
gation	 in	20%	BSA,	 a	 second	digestion	was	performed	using	1	mg/mL	 
collagenase/dispase	 (Roche)	 for	 50	minutes	 at	 37°C.	Microvessel	 frag-
ments	were	collected	after	centrifugation	on	Percoll	(Sigma	Aldrich)	gra-
dient	(10	minutes	on	1000g)	and	plated	onto	fibronectin/collagen-	coated	
dishes.	Endothelial	cells	growing	out	of	the	microvessels	were	cultured	in	
DMEM	Nutrient	F-	12	Ham	(DMEM/F12,	Thermo	Fischer	Scientific),	10%	
plasma-	derived	serum	(PDS,	First	Link),	insulin-	transferrin-	sodium	selenite	
(ITS)	supplement	(Sigma	Aldrich),	heparin	(Sigma	Aldrich)	and	basic	fibro-
blast	growth	factor	(bFGF,	Sigma	Aldrich).	In	the	first	2	days,	4	μg/mL	pu-
romycin	was	added	to	the	culture	medium	to	remove	contaminating	cells.
Endothelial-	tumour	cell	co-	cultures	were	prepared	as	previously	
described.15,16	Briefly,	brain	endothelial	cells	were	cultured	until	con-
fluence	in	filter	inserts	(Corning-	Costar	Transwell	Clear,	Corning,	NY,	
USA;	for	electron	microscopy),	microscope	slides	(ibidi,	for	immuno-
fluorescence),	culture	dishes	(for	Western	blot)	or	E-	plates	(for	imped-
ance	measurements).	Tumour	cells	were	seeded	upon	the	endothelial	
monolayer	in	a	density	of	0.5-	1.5	×	105	cells/cm2	surface	and	left	for	
5-	24	hours.	CellTracker	Red	CMTPX	(Thermo	Fisher	Scientific)	stain-
ing	was	performed	according	to	the	manufacturer's	instructions.
2.2 | In vivo brain metastasis models
For	 transmission	 electron	 microscopy	 (TEM)	 studies,	 Balb/c	 mice	
were	 injected	with	EmGFP-	4T1	cells.	For	confocal	microscopy,	we	
used	the	FVB/Ant:TgCAG-	yfp_sb	#27mouse	line	(obtained	from	the	
Institute	of	Experimental	Medicine,	Budapest,	Hungary)	expressing	
Venus-	YFP	 (yellow	 fluorescent	 protein)	 in	 endothelial	 cells.	 These	
animals	 were	 inoculated	 with	 tdTomato-	4T1	 cells.	 All	 mice	 were	
housed	and	treated	 in	accordance	with	widely	accepted	standards	
and	the	protocols	were	approved	by	the	 institutional	care	and	the	
Regional	 Animal	 Health	 and	 Food	 Control	 Station	 of	 Csongrád	
County	(permit	numbers:	XVI./2980/2012	and	XVI./764/2018).
Animals	were	injected	with	100	μL	Ringer-	Hepes	buffer	contain-
ing	 106	 tumour	 cells	 into	 the	 common	 carotid	 artery	 (for	 TEM)	 or	
3	×	106	tumour	cells	into	the	left	ventricle	(for	immunofluorescence),	
under	isoflurane	anaesthesia.	Animals	were	killed	after	5	or	12	days,	
transcardially	perfused	with	phosphate	buffered	saline	(PBS,	10	mol	
L−1,	pH	=	7.4),	then	with	2.7%	glutaraldehyde	(Sigma	Aldrich,	for	TEM)	
or	 3%	 paraformaldehyde	 (for	 immunofluorescence)	 in	 PBS.	 Brains	
were	removed	and	placed	into	the	same	fixative	overnight	at	4°C.
2.3 | Preparation of ultrasections and transmission 
electron microscopy (TEM)
Whole	brains	were	embedded	in	10%	gelatin	and	100	μm	sections	
were	 prepared	 using	 a	 Leica	 VT1000	 S	 vibratome.	 Sections	were	
examined	 under	 a	 fluorescence	 microscope.	 Sections	 containing	
EmGFP-	4T1	cells	were	further	used.
The	 filter	 inserts	 or	 the	 selected	 brain	 slices	 were	 fixed	 for	
2.5	hours	 in	2.7%	glutaraldehyde	 and	post-	fixed	 for	75	minutes	 in	
2%	 osmium	 tetroxide.	 After	 dehydration	 in	 graded	 ethanol	 baths,	
the	samples	were	immersed	in	graded	ethanol-	Epon	baths	and	then	
embedded	in	Epon	812.	The	blocks	were	cut	with	a	Leica	EM	UC7	
ultramicrotome,	and	the	50	nm	thick	sections	were	stained	with	ura-
nyl	acetate	and	lead	citrate,	then	analysed	with	a	Tecnai	12	Biotwin	
TEM.
2.4 | Immunofluorescence and 
fluorescence microscopy
Cell	cultures	were	fixed	with	100%	methanol	at	−20°C.	After	extensive	
washing	 in	PBS,	 samples	were	permeabilized	with	0.5%	TritonX-	100	
in	PBS	 at	 room	 temperature	 and	blocked	with	 3%	bovine	 serum	al-
bumin	 (BSA)	 in	PBS.	The	anti-	N-	cadherin	antibody	 (BD	Transduction	
Laboratories,	Franklin	Lakes,	NJ,	USA)	was	applied	on	 the	coverslips	
in	a	dilution	of	1:100	in	1%	BSA	in	PBS	overnight.	After	three	wash-
ings	 in	PBS,	coverslips	were	incubated	with	Alexa	Fluor	488-	labelled	
anti-	mouse	 IgG	 secondary	 antibody	 (Jackson	 ImmunoResearch,	
Cambridgeshire,	UK),	dilution:	1:100.	After	three	further	washing	steps,	
samples	were	mounted	with	FluoroMount-	G	media	(SouthernBiotech,	
Birmingham,	AL,	USA).	Nuclear	staining	was	performed	with	Hoechst	
33342	(0.66	μg/mL)	during	the	second	washing	step.	Fluorescent	sig-
nals	were	examined	with	a	Nikon	Eclipse	TE2000U	microscope.
Brain	 sections	were	prepared	with	 a	Reichert-	Jung	Cryo	mi-
crotome	1206.	After	post-	fixation,	brains	were	cryoprotected	in	
30%	sucrose	(in	10	mmol	L−1	PBS)	at	4°C.	Twenty	micrometres	of	
cryosections	 were	 prepared	 and	 used	 for	 immunofluorescence.	
Brain	 sections	 were	 placed	 in	 plates	 and	 subjected	 to	 antigen	
retrieval	using	100%	methanol	 for	30	minutes.	Permeabilization	
was	 performed	 with	 0.5%	 TritonX-	100	 for	 30	minutes	 at	 room	
temperature,	followed	by	blocking	with	3%	BSA	in	PBS.	The	first	
antibody	was	applied	in	a	dilution	of	1:100	in	1%	BSA	overnight	
at	 4°C.	 After	 washing	 in	 PBS,	 the	 secondary	 antibody	 (STAR	
RED	anti-	mouse	IgG;	Abberior,	Göttingen,	Germany)	was	applied	
in	 a	 dilution	 of	 1:500	 in	 PBS	 for	 1	hour	 at	 room	 temperature.	
After	 three	 further	washing	 steps,	 samples	were	mounted	with	
FluoroMount-	G	 media	 (SouthernBiotech).	 Nuclear	 staining	 was	
performed	with	Hoechst	33342	 (0.66	μg/mL)	during	 the	second	
washing	step.	Fluorescent	signals	were	examined	with	a	Leica	SP5	
confocal	laser	scanning	microscope.
2.5 | Cell sorting and Western blot
EGFP-	MDA-	MB-	231	 cells	 were	 co-	cultured	 with	 D3	 cells	 for	
24	hours.	Cells	were	 collected	with	 accutase	 (Corning)	 and	 sorted	
with	a	BD	FACSJazz	stream-	in-	air	cell	sorter	using	the	488	nm	laser.	
Mono-	cultured	EGFP-	MDA-	MB-	231	cells	or	D3	cells	were	also	col-
lected	with	accutase,	sorted	and	collected	based	on	the	gating	pa-
rameters	established	when	sorting	the	co-	cultured	cells.
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Cells	 were	 collected	 in	 radioimmunoprecipitation	 assay	 (RIPA)	
buffer.	After	the	30-	minute	incubation	on	ice,	cell	lysates	were	cen-
trifuged	on	9500g	for	30	minutes	at	4°C.	Protein	concentration	was	
determined	with	bicinchoninic	acid	(BCA)	(Santa	Cruz	Biotechnology,	
Santa	 Cruz,	 CA,	 USA).	 Laemmli	 buffer	 was	 added	 to	 the	 samples	
followed	by	heating	on	95°C	 for	3	minutes.	 Proteins	were	 electro-
phoresed	using	standard	denaturing	SDS-	PAGE	procedures	and	blot-
ted	 on	 polyvinylidene	 difluoride	 (PVDF)	 or	 nitrocellulose	 (Bio-	Rad,	
Hercules,	CA,	USA)	membranes.	Afterwards,	the	non-	specific	binding	
capacity	of	the	membranes	was	blocked	with	3%	BSA	or	5%	non-	fat	
milk	in	TBS-	T	(Tris-	buffered	saline	with	0.1%	Tween-	20).	Membranes	
were	 incubated	with	primary	antibodies	 in	TBS-	T	using	 the	 follow-
ing	dilutions:	1:200	cofilin	(Cell	Signaling	Technology,	Danvers,	MA,	
USA),	 1:200	 phospho-	cofilin	 (Cell	 Signaling	 Technology),	 1:1000	
β-	actin	 (Sigma	 Aldrich),	 1:500	 pan-	cytokeratin	 (Thermo	 Fischer	
Scientific),	 1:250	 claudin-	5	 (Thermo	 Fischer	 Scientific)	 or	 1:200	N-	
cadherin	(BD	Transduction	Laboratories).	Blots	were	washed	in	TBS-	T	
and	 incubated	with	 the	 secondary	 antibodies	 in	 TBS-	T,	 as	 follows:	
HRP-	conjugated	anti-	rabbit	IgG	(1:1000,	Cell	Signalling	Technology)	
or	 HRP-	conjugated	 anti-	mouse	 IgG	 (1:4000,	 BD	 Transduction	
Laboratories).	 After	washing,	 immunoreaction	was	 visualized	 using	
the	Clarity	Chemiluminescent	Substrate	(Bio-	Rad)	in	a	ChemiDoc	MP	
imaging	system	(Bio-	Rad).	 Image	lab	software	version	5.2	(Bio-	Rad)	
was	used	for	the	quantification	of	the	blots	by	densitometry.
2.6 | Real- time impedance monitoring
To	 monitor	 the	 effects	 of	 tumour	 cells	 on	 RBECs	 in	 real	 time,	
we	 measured	 the	 electrical	 impedance	 using	 the	 xCELLi-
gence	 system	 following	 the	 manufacturer's	 instructions	 (Acea	
Biosciences).	Briefly,	 cells	were	seeded	 in	an	E-	plate	 (ie,	96-	well	
tissue	 culture	 plates	 having	 micro-	electrodes	 integrated	 on	 the	
bottom)	 and	 allowed	 to	 attach	 onto	 the	 electrode	 surface	 over	
time.	 The	 electrical	 impedance	was	 recorded	 every	 30	minutes.	
When	the	impedance	reached	plateau	(ie	the	monolayer	reached	
confluence),	 the	 cells	were	 treated	 overnight	with	 550	nmol	 L−1 
F IGURE  1 Adhesion	of	melanoma	cells	and	intercalation	between	endothelial	cells.	B16/F10	melanoma	cells	were	seeded	on	the	top	
of	confluent	RBEC	monolayers	and	left	for	8	hours.	Representative	transmission	electron	micrographs	show:	a	melanoma	cell	attached	
to	brain	endothelial	cells	in	close	proximity	to	the	interendothelial	junctions	(A);	a	melanoma	cell	attached	distant	to	the	junctions	(B)	and	
a	melanoma	cell	intercalated	between	endothelial	cells	(C).	Arrows	indicate	interendothelial	junctions.	Arrowheads	point	to	endothelial	
membrane	protrusions.	EC	=	endothelial	cell
A
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hydrocortisone,	 250	μmol	 L−1	 CPT-	cAMP	 and	 17.5	μmol	 L−1	 RO-	
201724	(Sigma	Aldrich)	to	induce	maturation	of	TJs.	Tumour	cells	
(2	×	104)	were	 seeded	 into	 the	wells	 in	a	medium	containing	 re-
duced	serum	levels	(2.5%)	and	left	for	8	hours.	The	cell	impedance	
(which	depends	on	cell	number,	degree	of	adhesion,	spreading	and	
proliferation	of	the	cells	and	also	the	tightness	of	the	junctions),	
expressed	 in	arbitrary	units	 (cell	 index)	was	automatically	calcu-
lated	by	the	software	of	the	instrument.
FIGURE 2 Transmigration	of	melanoma	cells	through	brain	endothelial	layers.	Melanoma	cells	(A,	C:	B16/F10;	B,	D:	A2058)	were	seeded	
on	the	top	of	confluent	RBEC	monolayers	and	left	for	8	hours.	(A	and	B)	Electron	micrograph	series	of	transmigrating	melanoma	cells.	(C	and	D)	
Representative	transmission	micrographs	of	melanoma	cells	migrated	through	the	brain	endothelial	monolayer.	Arrow	=	interendothelial	junction,	
arrowhead	=	membrane	protrusion,	EC	=	endothelial	cell
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3  | RESULTS
3.1 | Interactions of melanoma cells with brain 
endothelial cells in vitro
Since	 our	 previous	 results	 indicated	 that	melanoma	 cells	 have	 in-
creased	ability	to	attach	to	and	to	migrate	through	brain	endothelial	
cells	 than	 breast	 cancer	 cells,	we	 aimed	 to	 investigate	 these	 phe-
nomena	at	ultrastructural	level.
We	 first	 focused	on	 the	 adhesion	 step,	which	 precedes	 trans-
migration	 of	 tumour	 cells	 through	 endothelial	 cells.	We	 observed	
several	melanoma	cells	attached	 to	brain	endothelial	 cells	 in	close	
proximity	 to	 the	 interendothelial	 junctions	 (Figure	1A),	 but	 also	 in	
regions	 distant	 from	 endothelial-	endothelial	 contacts	 (Figure	1B).	
Brain	 endothelial	 cells	 extended	 filopodia-	like	 membrane	 pro-
trusions	 towards	 melanoma	 cells	 (Figure	1B),	 probably	 having	 an	
important	role	in	the	intercalation	of	the	tumour	cell	between	endo-
thelial	cells	(Figure	1C).
As	 a	 result,	 melanoma	 cells	 transmigrated	 paracellularly,	
through	the	tight	and	adherens	junctions	between	endothelial	cells	
(Figure	2A	and	B).	Some	melanoma	cells	attached	in	clusters	to	the	
brain	 endothelial	 monolayer	 (Figure	2A)	 facilitating	 utilization	 of	
the	same	transmigration	path	by	more	cells,	as	we	have	previously	
shown.15,16	We	could	also	see	transmigrated	melanoma	cells	on	the	
basolateral	 side	 of	 the	 endothelial	 cells.	 Transmigrated	melanoma	
cells	either	moved	further	underneath	the	intact	endothelial	mono-
layer	(Figure	2C)	or,	more	often,	were	seen	in	the	neighbourhood	of	
the	damaged	endothelial	cells	(Figure	2D).
3.2 | Interactions of breast cancer cells with brain 
endothelial cells in vitro
Similar	to	melanoma	cells,	we	could	also	identify	breast	cancer	cells	
attached	 to	 cerebral	 endothelial	 junctions	 (Figure	3A	 and	 B),	 al-
though	less	in	number.	In	the	proximity	of	these	cells,	filopodia-	like	
endothelial	protrusions	could	be	seen,	similar	to	those	observed	in	
the	vicinity	of	melanoma	cells.
We	 have	 also	 detected	 several	 breast	 cancer	 cells	 completely	
covered	by	endothelial	processes,	incorporating	the	tumour	cell	into	
the	monolayer	(Figure	3C	and	D).	Endothelial	TJs	were	only	observed	
on	the	top	of	or	lateral	to	the	mammary	cancer	cells,	and	were	ab-
sent	beneath	the	tumour	cells,	in	the	direction	of	migration.	Similar	
integration	of	cancer	cells	 into	 the	brain	endothelial	 layer	was	not	
observed	for	melanoma	cells.	Moreover,	the	endothelial	monolayer	
remained	almost	perfectly	 intact	despite	 the	presence	of	 transmi-
grated	tumour	cells	(Figure	3E	and	F).
We	have	suggested	that	actin	reorganization	might	play	an	im-
portant	role	in	the	changes	observed	in	endothelial	cells,	 including	
membrane	 protrusion	 formation,	 tumour	 cell	 incorporation	 and	
junctional	disassembly.	Recently,	CECs	were	suggested	to	activate	
cofilin	in	response	to	extracellular	vesicles	secreted	by	breast	cancer	
cells.21	 To	 study	 the	 involvement	of	 this	 signalling	pathway	 in	our	
system,	we	co-	cultured	EGFP-	expressing	MDA-	MB-	231	breast	can-
cer	cells	with	D3	brain	endothelial	cells.	After	24	hours,	we	sorted	
the	two	cell	types	based	on	green	fluorescence.	Purity	of	the	sorted	
samples	was	assessed	by	expression	of	cytokeratin	in	tumour	cells,	
but	not	in	endothelial	cells	and	expression	of	claudin-	5	in	endothelial	
cells,	but	not	in	tumour	cells.	Phospho-	cofilin	was	highly	expressed	
in	control	brain	endothelial	cells,	but	significantly	decreased	in	cells	
co-	cultured	with	breast	 cancer	 cells	 (Figure	3G	and	H),	 suggesting	
activation	of	cofilin	signalling	in	CECs	in	the	presence	of	breast	can-
cer	cells.
Previously,	we	have	shown	that	melanoma	cells,	but	not	mam-
mary	carcinoma	cells,	can	effectively	disrupt	cerebral	endothelial	TJs	
to	migrate	through	the	paracellular	pathway.15,16	In	order	to	under-
stand	the	effect	of	melanoma	and	breast	cancer	cells	on	the	integrity	
of	the	brain	endothelium,	we	followed	the	impedance	of	the	mono-
layers	after	seeding	different	tumour	cells	upon	them.	Both	B16/F10	
and	A2058	melanoma	cells	significantly	decreased	the	impedance	of	
brain	endothelial	cells	already	after	2	hours	(Figure	4A).	Neither	of	
the	four	breast	cancer	cell	lines	had	significant	effect	on	the	imped-
ance.	These	data	suggest	that	melanoma,	but	not	breast	cancer	cells	
are	able	to	significantly	impair	TJs	of	CECs.	These	results	raised	the	
possibility	of	transcellular	migration	of	breast	cancer	cells.
Using	electron	microscopy,	here	we	show	for	the	first	time	that	
breast	 cancer	 cells	 are	 able	 to	 utilize	 the	 transcellular	 pathway—
through	individual	endothelial	cells—during	their	migration	from	the	
apical	to	the	basolateral	side	of	cerebral	endothelial	cells	(Figure	4B	
and	C).
3.3 | Role of N- cadherin in the transendothelial 
migration of tumour cells
Besides	 disruption	 of	 TJs,	 melanoma	 cells	 must	 open	 the	 AJs	 of	
CECs	during	their	paracellular	migration	from	the	apical	to	the	baso-
lateral	 side	 of	 the	 endothelium.	 N-	cadherin-	mediated	 interaction	
was	 shown	 to	be	 involved	 in	 this	process	 in	non-	brain	endothelial	
cells.17	 Therefore,	 we	 investigated	 involvement	 of	 N-	cadherin	 in	
F IGURE  3  Interactions	of	breast	cancer	cells	with	brain	endothelial	cells.	Breast	cancer	cells	(A,	C,	E,	F:	MDA-	MB-	231;	B,	D:	4T1)	were	
seeded	on	the	top	of	confluent	RBEC	monolayers	and	left	for	8	hours.	Representative	transmission	electron	micrographs	show	the	adhesion	
(A,	B)	and	incorporation	(C,	D)	steps.	(A)	Bottom	panel	is	a	higher	magnification	of	the	image	in	the	top	panel.	(E	and	F)	Transmigrated	
breast	cancer	cells.	Interendothelial	junctions	are	indicated	with	black	arrows,	endothelial	membrane	protrusions	are	marked	with	black	
arrowheads.	(G)	EGFP-	MDA-	MB-	231	cells	were	co-	cultured	with	D3	cells.	After	24	hours,	the	two	cell	types	were	separated	by	sorting.	
Representative	Western	blot	images	are	shown.	Purity	of	the	samples	is	shown	by	the	absence	of	epithelial-	specific	cytokeratin	in	
endothelial	cells	and	absence	of	endothelial-	specific	claudin-	5	in	the	tumour	cells.	(H)	Quantification	of	p-	cofilin	protein	levels	normalized	
to	cofilin	(average	±	SD),	based	on	the	Western	blot	images.	N	=	3	independent	experiments.	*P	<	0.01	as	assessed	by	Student's	t	test	(when	
endothelial	cell—EC—mono	and	co-	cultures	were	compared)
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the	migration	of	melanoma	and	breast	 cancer	 cells	 through	CECs.	
When	melanoma	cells	were	seeded	upon	a	confluent	monolayer	of	
CECs,	 tumour	cells	 tended	 to	 rapidly	 intercalate	among	CECs.	We	
observed	the	appearance	of	N-	cadherin	in	the	melanoma-	melanoma	
and	 melanoma-	endothelial	 contact	 regions	 (Figure	5A).	 However,	
almost	 no	 N-	cadherin	 was	 detected	 in	 endothelial-	breast	 cancer	
cell	co-	cultures	(Figure	5B).	Our	Western	blot	results	indicated	that	
both	A2058	and	B16/F10	melanoma	cells	expressed	high	 levels	of	
N-	cadherin,	but	no	N-	cadherin	protein	was	detected	 in	our	breast	
cancer	cell	lines	(Figure	5C).
Therefore,	 as	 a	 next	 step	 we	 investigated	 the	 ability	 of	 
N-	cadherin-	negative	 breast	 cancer	 cells	 to	 give	 brain	 metastases	
in	 vivo.	As	 a	unique	 feature	of	brain	metastasis	 formation,	 tumour	
cells	 arrested	 in	 cerebral	 capillaries	 survive	 for	 long	 time	 (approxi-
mately	3-	5	days)	intravascularly	before	completing	transmigration.12 
Therefore,	the	first	timepoint	studied	in	the	in	vivo	setup	was	day	5	
after	the	injection	of	the	tumour	cells	into	the	circulation	of	mice.	At	
this	timepoint,	we	observed	transmigrating	tumour	cells	which	were	
all	N-	cadherin	negative	(Figure	6A).	On	the	other	hand,	expression	of	
N-	cadherin	was	 induced	 in	the	cerebral	endothelium	in	the	vicinity	
of	some	of	the	transmigrating	cells	 (Figure	6A).	By	day	12	after	the	
inoculation,	several	micro-	and	macrometastatic	lesions	were	formed	
in	the	brain	parenchyma.	Importantly,	4T1	cells	remained	N-	cadherin	
negative	 throughout	 the	 metastatic	 process.	 N-	cadherin	 was	 only	
detected	 in	some	vascular	 segments	 in	 the	endothelium	of	 tumour	
cell-	bearing	mice	(Figure	6B).	These	results	suggest	that	N-	cadherin	
is	not	necessarily	needed	by	breast	cancer	cells	to	migrate	through	
the	brain	vasculature	and	to	form	metastases	in	the	CNS.
3.4 | Interactions of breast cancer cells with the 
brain endothelium in vivo
Finally,	we	examined	 interactions	of	metastatic	breast	cancer	cells	
with	the	brain	endothelium	in	vivo	using	TEM.	In	the	brain	sections	
obtained	 from	 mice	 injected	 with	 breast	 carcinoma	 cells,	 we	 ob-
served	active	involvement	of	CECs	in	the	metastatic	extravasation	
process.	Endothelial	protrusions	covering	extravasating	cancer	cells	
were	seen	(Figure	7A	and	B).
4  | DISCUSSION
Development	of	brain	metastases	is	largely	dependent	on	the	abil-
ity	of	the	tumour	cells	to	migrate	through	the	tightest	endothelium	
of	the	organism,	which	forms	the	BBB.	Involvement	of	CECs	in	ex-
travasation	of	cancer	cells	 into	 the	CNS	 is	 largely	uncharacterized	
and	might	be	both	offensive	and	defensive	at	 the	 same	 time	with	
the	 invading	 cells.12	 By	 using	 TEM—a	 high	 resolution	morphology	
technique—we	assessed	interactions	of	CECs	with	two	of	the	most	
aggressive	brain	metastatic	cells,	that	is	melanoma	and	triple	nega-
tive	breast	cancer	cells.
Our	 in	 vitro	 and	 in	 vivo	 results	 indicate	 that	CECs	play	 an	 ac-
tive	 role	 in	 the	 transendothelial	 migration	 of	 the	 tumour	 cells	 by	
extending	filopodia-	like	processes,	which	might	guide	invading	cells	
towards	low	resistance	points.22	Through	this	mechanism,	endothe-
lial	cells	may	also	incorporate	the	tumour	cells	or	their	extracellular	
vesicles,	or	isolate	them	from	the	circulating	blood	in	vivo.	Further	
studies	are	needed	to	understand	whether	this	 is	a	“friend	or	foe”	
reaction	of	endothelial	cells,	that	is,	whether	endothelial	protrusions	
facilitate	 transendothelial	 migration	 or	 engulf	 the	 tumour	 cells	 to	
protect	the	brain.
The	observed	ruffling	of	the	endothelial	plasma	membrane	
is	reminiscent	of	macropinocytosis,23	which	 is	the	entry	route	
for	 platelet-	derived	 microparticles,24	 pathogenic	 Escherichia 
coli bacteria 25	and	nanoparticles	26	through	the	BBB.	However,	
molecular	mechanisms	of	 tumour-	endothelial	 interactions	still	
need	 to	 be	 studied.	 Cofilin	 activation	 indicates	 involvement	
of	 the	 actin-	myosin	 network.	 Nevertheless,	 cofilin-	induced	
modulation	 of	 actin	 dynamics	 in	 CECs	 has	 been	 shown	 to	
promote	 transendothelial	 migration	 of	 breast	 cancer	 cells	
and	 formation	of	brain	metastases	 in	vivo.21	According	 to	 the	
study	 of	 Tominaga	 et al,21	 breast	 cancer-	derived	 extracellu-
lar	 vesicles	 containing	miR-	181c	 promote	 destruction	 of	 BBB	
TJs	 through	 reorganization	 of	 actin,	 via	 down-	regulation	 of	
3-	phosphoinositide-	dependent	 protein	 kinase-	1	 (PDPK1)	 and	
down-	regulation	 of	 phospho-	cofilin	 (i.e.	 activation	 of	 cofilin).	
Therefore,	 remodelling	 of	 the	 endothelial	 cytoskeleton	might	
be	 actively	 involved	 in	 regulating	 interactions	 of	 cancer	 cells	
with	 the	 cerebral	 endothelium.	 Nevertheless,	 the	 exact	 role	
of	membrane	 and	 cytoskeletal	 changes	 of	 the	 cerebral	 endo-
thelium	in	the	metastatic	process	is	far	from	being	completely	
understood.
Among	brain	metastatic	tumours,	melanoma	has	the	highest	af-
finity	towards	the	CNS.	Earlier,	this	has	been	explained	by	the	good	
capacity	of	melanoma	cells	to	proliferate	in	the	brain	parenchyma.27 
However,	our	previous	results	suggested	that	melanoma	cells	might	
also	have	an	increased	ability	to	migrate	through	cerebral	endothelial	
layers	in	comparison	to	breast	cancer	cells.16	Especially,	impairment	
of	TJs	of	CECs	was	more	pronounced	in	the	presence	of	melanoma	
than	mammary	cancer	cells.
Our	present	results	are	in	line	with	these	data,	showing	that	
melanoma	 cells	 can	 effectively	 use	 the	 paracellular	 route	 of	
transmigration.	As	a	preceding	 step,	melanoma	cells	 intercalate	
between	endothelial	cells,	which	has	previously	been	referred	to	
as	“incorporation”.14	However,	based	on	the	differences	between	
diapedesis	of	melanoma	and	breast	cancer	cells	through	cerebral	
endothelial	cells,	presented	here,	we	suggest	using	the	term	“in-
tercalation”	when	tumour	cells	localize	between	two	endothelial	
cells	 to	 proceed	 further	 to	 the	 paracellular	 transmigration.	We	
use	 the	 term	 “incorporation”	 for	 describing	 tumour	 cells—inde-
pendently	 whether	 intact	 or	 not—completely	 covered	 by	 en-
dothelial	 cells.	 This	 phenomenon	 was	 mostly	 seen	 with	 breast	
cancer	cells,	most	 likely	 linked	to	the	transcellular	type	of	tran-
sendothelial	migration.
To	 our	 best	 knowledge,	we	 are	 the	 first	 to	 show	 direct	 evi-
dence	of	transcellular	migration	of	tumour	cells	through	the	BBB.	
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The	transcellular	route	of	migration	has	initially	been	recognized	
for	 leukocytes,28	 especially	 in	 the	 brain	 microvasculature.29,30 
As	for	tumour	cells,	the	transcellular	route	of	migration	has	only	
been	described	 in	 the	 diapedesis	 of	 breast	 cancer	 cells	 through	
an	 in	vitro	vascular	network	31	or	 through	human	umbilical	cord	
endothelial	cells	 (HUVECs).32	During	this	process	an	actomyosin	
transcellular	 circumferential	 invasion	 array	 is	 formed,	 regulated	
by	myosin	light	chain	kinase	(MLCK)	and	myosin	II	regulatory	light	
chain	 (RLC)	 phosphorylation.	 Further	 studies	 are	 needed	 to	 un-
derstand	which	signalling	pathways	are	involved	in	the	regulation	
of	 the	cerebral	 endothelial	 cytoskeleton	during	 transcellular	mi-
gration	of	breast	cancer	cells.
F IGURE  4 Transcellular	migration	of	breast	cancer	cells	through	brain	endothelial	cells.	(A)	Tumour	cells	were	seeded	onto	confluent	
monolayers	of	RBECs	cultured	in	E-	plates	and	left	for	8	hours.	Impedance	of	the	cells	(represented	by	the	cell	index)	was	followed	using	the	
ACEA	xCELLigence	system.	Results	are	expressed	as	%	control	and	given	as	mean	±	SEM.	N	=	4,	*P	<	0.01	(A2058	and	B16/F10	melanoma	
cells	compared	to	control)	as	assessed	by	ANOVA	and	Bonferroni's	post-	hoc	test.	(B)	MDA-	MB-	231	cells	were	seeded	onto	a	confluent	
monolayer	of	RBECs	and	left	for	8	hours.	Images	presented	are	electron	micrograph	series	of	a	transmigrating	breast	cancer	cell.	Arrows	
indicate	interendothelial	junctions.	(C)	Higher	magnification	pictures	of	the	respective	images	shown	in	(B).	EC	=	endothelial	cell
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During	paracellular	migration,	melanoma	cells	disrupt	the	
TJs	of	CECs.15	Not	only	TJs,	but	AJs	are	also	 involved	 in	this	
process.	Melanoma	 cells	 may	 adhere	 in	 clusters	 to	 cerebral	
endothelial	cells,	and	attach	to	each	other	and	to	endothelial	
cells	 through	 N-	cadherin-	mediated	 junctions.	 As	 previously	
shown,	 the	recruitment	of	N-	cadherin	to	heterocellular	con-
tacts	plays	an	important	role	 in	the	interaction	of	melanoma	
cells	with	non-	cerebral	endothelial	cells	during	transendothe-
lial	 migration.17,33	 Moreover,	 after	 long-	lasting	 interactions,	
tumour	cells	are	able	to	up-	regulate	N-	cadherin	expression	in	
CECs	during	endothelial-	mesenchymal	 transition	 to	enhance	
transendothelial	migration.18	Here	we	show	that	N-	cadherin	
is	mainly	 involved	 in	melanoma-	endothelial	 interactions,	but	
is	 dispensable	 in	 the	 transendothelial	 migration	 of	 breast	
cancer	 cells	 both	 in	 vitro	 and	 in	 vivo.	 A	 few	 days	 after	 the	
injection	 of	 breast	 cancer	 cells	 into	 the	 mice,	 we	 observed	
up-	regulation	of	N-	cadherin	 in	brain	microvascular	endothe-
lial	cells;	however,	4T1	breast	cancer	cells	did	not	up-	regulate	
N-	cadherin	 expression	 either	 before,	 or	 during	 or	 after	 ex-
travasation.	This	indicates	an	N-	cadherin-	independent	trans-
migration	 of	 breast	 cancer	 cells	 in	 our	 in	 vitro	 and	 in	 vivo	
models,	which	might	explain	the	lower	transmigration	ability	
of	breast	cancer	cells	in	comparison	to	melanoma	cells,	as	we	
have	previously	observed.16
Taken	 together,	 our	 results	 indicate	 that—through	 cytoskele-
tal	 and	 membrane	 reorganization—the	 microvascular	 endothelium	
F IGURE  5 Role	of	N-	cadherin	in	the	transendothelial	migration	of	tumour	cells	in	vitro.	(A)	CellTracker	Red	CMTPX-	stained	A2058	
melanoma	cells	were	seeded	onto	a	confluent	monolayer	of	D3	cells	and	left	for	5	hours.	Representative	immunofluorescence	images	are	
shown.	The	two	bottom	panels	(i	and	ii)	are	higher	magnifications	of	the	respective	sectors	in	the	top	image.	(B)	CellTracker	Red	CMTPX-	
stained	MDA-	MB-	231	cells	were	seeded	onto	a	confluent	monolayer	of	D3	cells	and	left	for	5	hours.	Representative	immunofluorescence	
images	are	shown.	The	two	bottom	panels	(iii	and	iv)	are	higher	magnifications	of	the	respective	sectors	in	the	top	image.	(C)	MDA-	MB-	231	
or	4T1	breast	cancer	or	A2058	or	B16/F10	melanoma	cells	were	seeded	onto	confluent	monolayers	of	RBECs	and	left	for	5	hours.	Protein	
samples	were	collected	from	mono-	cultures	or	co-	cultures	(mixed	cells).	Representative	Western	blot	shows	expression	of	N-	cadherin	in	
brain	endothelial	and	melanoma	cells,	but	not	in	breast	cancer	cells	(MDA-	MB-	231	and	4T1).	EC	=	endothelial	cell
F IGURE  6 Role	of	N-	cadherin	in	the	transendothelial	migration	of	breast	cancer	cells	in	vivo.	4T1	mouse	triple	negative	breast	cancer	
cells	expressing	tdTomato	red	fluorescent	protein	were	injected	into	mice	expressing	Venus-	YFP	in	endothelial	cells.	Mice	were	killed	after	
5	or	12	days	(A	and	B,	respectively).	Representative	confocal	micrographs	show	that	4T1	breast	cancer	cells	are	N-	cadherin	negative	and	
metastasize	efficiently	to	the	brain.	(A)	Transmigrating	cell	in	day	5	after	inoculation	of	tumour	cells	(indicated	by	white	arrow).	(B)	Already	
formed	metastatic	lesions	in	day	12.	(a)	nuclei	(Hoechst	33342	staining).	(b)	endothelial	cells	(Venus-	YFP).	(c)	tdTomato-	4T1	cells.	(d)	N-	
cadherin	staining.	(e)	merged	image	of	(b)	and	(d).	(f)	merged	image	of	(a)-(d).	(g)	merged	image	of	(c)	and	(d)
     |  2629HERMAN Et Al.
A
B
a
a
e
f g
b c d
e f g
b c d
2630  |     HERMAN Et Al.
is	directly	 involved	 in	extravasation	of	 tumour	cells	 into	 the	brain.	
We	also	show	that	melanoma	cells	primarily	utilize	the	paracellular	
route	 of	 transendothelial	 migration,	 while	 breast	 cancer	 cells	 are	
able	 to	 transcellularly	 migrate	 through	 the	 brain	 endothelial	 cell	
layer.	 During	 extravasation	 into	 the	 brain,	 triple	 negative	 breast	
cancer	cells	can	migrate	through	the	vessel	walls	in	an	N-	cadherin-	
independent	manner.
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